Natera, Inc. (NTRA)
| Market Cap | 44.68B +103.7% |
| Revenue (ttm) | 2.71B +37.8% |
| Net Income | -192.35M |
| EPS | -1.37 |
| Shares Out | 144.14M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,017,616 |
| Open | 308.01 |
| Previous Close | 310.78 |
| Day's Range | 305.00 - 311.99 |
| 52-Week Range | 152.62 - 326.03 |
| Beta | 1.51 |
| Analysts | Buy |
| Price Target | 330.64 (+6.66%) |
| Earnings Date | Aug 6, 2026 |
About NTRA
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizo... [Read more]
Financial Performance
In 2025, Natera's revenue was $2.31 billion, an increase of 35.90% compared to the previous year's $1.70 billion. Losses were -$208.16 million, 9.31% more than in 2024.
Financial StatementsAnalyst Summary
According to 22 analysts, the average rating for NTRA stock is "Buy." The 12-month stock price target is $330.64, which is an increase of 6.66% from the latest price.
News
Natera Transcript: Canaccord Genuity's 46th Annual Growth Conference
Q2 saw record growth in all segments, with standout performance in organ health and oncology. Product innovation, robust clinical data, and expanded reimbursement are fueling momentum, while global expansion and major investments in lab capacity and early cancer detection position the business for sustained growth.
Natera to Support New Clinical Trial Assessing ctDNA Dynamics with Latitude™ in Advanced Skin Cancers
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a new collaboration regarding a Phase 1 clinical trial, sponsored ...
Natera price target raised to $355 from $310 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Natera (NTRA) to $355 from $310 and keeps an Overweight rating on the shares.
Natera Shares Soar Over 20% To All-Time High, Bolstering Co-Founder's Billionaire Status
40.6%. That is how much Natera shares have grown since the start of the year, when they were priced around the $228 mark. The company's lowest closing price this year occurred in late March, when shar...
Natera price target raised to $340 from $325 at TD Cowen
TD Cowen raised the firm’s price target on Natera (NTRA) to $340 from $325 and keeps a Buy rating on the shares. The firm updated its model following Q2 results.
Natera price target raised to $360 from $300 at Evercore ISI
Evercore ISI analyst Daniel Markowitz raised the firm’s price target on Natera (NTRA) to $360 from $300 and keeps an Outperform rating on the shares.
Natera price target raised to $350 from $275 at RBC Capital
RBC Capital raised the firm’s price target on Natera (NTRA) to $350 from $275 and keeps an Outperform rating on the shares.
Natera price target lowered to $348 from $379 at Baird
Baird analyst Catherine Ramsey Schulte lowered the firm’s price target on Natera (NTRA) to $348 from $379 and keeps an Outperform rating on the shares. The firm updated its model…
Natera price target raised to $375 from $330 at Canaccord
Canaccord analyst Kyle Mikson raised the firm’s price target on Natera (NTRA) to $375 from $330 and keeps a Buy rating on the shares. The firm said their price target…
Natera price target raised to $360 from $315 at JPMorgan
JPMorgan raised the firm’s price target on Natera (NTRA) to $360 from $315 and keeps an Overweight rating on the shares post the Q2 report. The company reported an “exceptional”…
Natera price target raised to $284 from $220 at Wells Fargo
Wells Fargo raised the firm’s price target on Natera (NTRA) to $284 from $220 and keeps an Equal Weight rating on the shares. The firm notes Q2 revenue beat consensus…
Natera price target raised to $315 from $300 at Citi
Citi raised the firm’s price target on Natera (NTRA) to $315 from $300 and keeps a Buy rating on the shares.
Natera price target raised to $320 from $290 at BTIG
BTIG raised the firm’s price target on Natera (NTRA) to $320 from $290 and keeps a Buy rating on the shares. Natera delivered a strong Q2 with significant revenue upside,…
Natera price target raised to $330 from $280 at Leerink
Leerink raised the firm’s price target on Natera (NTRA) to $330 from $280 and keeps an Outperform rating on the shares.
Natera price target raised to $340 from $260 at Barclays
Barclays raised the firm’s price target on Natera (NTRA) to $340 from $260 and keeps an Overweight rating on the shares. The firm updated the company’s model following the earnings…
Natera reports Q2 EPS (47c), consensus (53c)
Reports Q2 revenue $752.8M, consensus $661.29M. “We had an exceptional quarter helping patients, with over one million tests processed for the second consecutive quarter and record growth in oncology ...
Natera raises FY26 revenue view to $2.85B-$2.91B, consensus $2.8B
Previous view $2.74B-$2.82B.
Natera Earnings Call Transcript: Q2 2026
Record test volumes and 38% revenue growth were driven by strong oncology and women's health performance, major regulatory wins for Signatera, and improved gross margins. Raised full-year guidance reflects confidence in continued volume and ASP growth.
Natera Earnings release: Q2 2026
Natera released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Natera Slides: Q2 2026
Natera has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 6, 2026.
Natera Quarterly report: Q2 2026
Natera has published its Q2 2026 quarterly earnings report on August 6, 2026.
Natera Reports Second Quarter 2026 Financial Results
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the second quarter ended June 30, 2026. Rece...
Natera submits Signatera test to Japan’s PMDA for approval as CDx
Natera (NTRA) announced that it has submitted an application to Japan’s Pharmaceuticals and Medical Devices Agency for approval of the Signatera test in muscle-invasive bladder cancer as a companion d...
Natera Submits Signatera™ to Japan's PMDA for Approval as a Companion Diagnostic in Muscle-Invasive Bladder Cancer
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it has submitted an application to Japan's Pharmaceuticals an...
Natera to Report its Second Quarter Results on August 6, 2026
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will release results for its second quarter ended June 30,...